ARTICLE. Compliance With Penicillin Prophylaxis in Patients With Sickle Cell Disease
|
|
- Gordon Miles
- 6 years ago
- Views:
Transcription
1 ARTICLE Compliance With Penicillin Prophylaxis in Patients With Sickle Cell Disease Stephen J. Teach, MD, MPH; Kathleen A. Lillis, MD; Mauro Grossi, MD Objective: To assess factors related to compliance with penicillin prophylaxis among patients with sickle cell disease. Design: Prospective case series. Setting: Urban pediatric medical center where universal penicillin prophylaxis is recommended for all patients with any sickle cell hemoglobinopathy independent of age. Participants: Eligible patients with sickle cell hemoglobinopathies were enrolled in either the emergency department or the sickle cell clinic. Main Outcome Measures: Compliance was assessed by structured interview and by urine assay with an established method (Micrococcus luteus with disk diffusion) that detects excreted penicillin up to 15 hours after each dose administration. Results: Of the 159 patients actively followed up at the sickle cell center, 123 (77.3%) eligible patients were enrolled. Reported compliance by structured interview ( 1 dose of penicillin V potassium within 15 hours of enrollment) was 83 of 123 patients (67.5%; 95% confidence interval, 59.2%-75.8%), whereas measured compliance as determined by urine assay was 53 of 123 patients (43.1%; 95% confidence interval, 31.3%- 51.7%). Measured compliance was significantly greater in patients younger than 5 years than in those older than 5 years (25/41 [61%] vs 28/82 [34%], respectively; P=.004), and was significantly greater in patients with private insurance than in those with public insurance (17/28 [61%] vs 33/90 [37%], respectively; P=.02). Measured compliance was not significantly associated with sex, site of recruitment, hemoglobinopathy, or chief complaint in the emergency department. Conclusions: Measured compliance was poor, and patients and/or their families frequently misrepresented their compliance when interviewed. These data suggest that efforts are necessary to improve overall compliance, and they identify groups at greatest risk for noncompliance. Arch Pediatr Adolesc Med. 1998;152: Editor s Note: I guess the official flower for the daily penicillin prophylaxis school is the forget-me-lots. Catherine D. DeAngelis, MD From the Department of Pediatrics, State University of New York at Buffalo School of Medicine and Biomedical Sciences and the Children s Hospital of Buffalo. Dr Teach is now with the Children s National Medical Center, George Washington University School of Medicine, Washington, DC. INFANTS and young children with sickle cell disease have long been known to be susceptible to bacteremia and meningitis due to Streptococcus pneumoniae. 1 Daily penicillin prophylaxis decreases episodes of pneumococcal bacteremia in patients with sickle cell disease younger than 5 years of age. 2 Current recommendations are to institute prophylaxis as soon as the diagnosis of sickle cell disease is established (preferably by 2 months of age) and to continue it at least through age 5 years. 3 Prophylaxis after age 5 years is optional, but is recommended in children with prior episodes of severe pneumococcal infection or splenectomy and in those not receiving comprehensive care. 4 Because the Sickle Cell Center at the Children s Hospital of Buffalo, Buffalo, NY, recommends continued penicillin prophylaxis for all patients regardless of age or underlying sickle cell hemoglobinopathy, it provides an ideal setting to examine factors related to compliance with prophylaxis in a group of patients receiving comprehensive care for sickle cell disease. RESULTS DEMOGRAPHICS During the 10-month study period, the sickle cell clinic actively followed up 159 patients with documented sickle cell hemoglobinopathy. Of these, 125 patients 274
2 PATIENTS AND METHODS We prospectively obtained a convenience sample of patients with sickle cell disease who presented to either the emergency department or the sickle cell clinic at the Children s Hospital of Buffalo during the 10- month study period (April 1996 through January 1997). An unselected subset of patients were enrolled more than once. It was the policy of the Sickle Cell Center at the Children s Hospital of Buffalo for at least 5 years before the start of the study and for the entire duration of the study that all patients with a sickle cell hemoglobinopathy receive penicillin V potassium prophylaxis in a dose of 125 mg twice daily prior to age 2 years and 250 mg twice daily after 2 years of age. Review of prophylaxis was a standard part of each clinic visit at all ages. The sickle cell clinic at Children s Hospital of Buffalo receives referrals from newborn screening and schedules patient visits every 2 months from birth to 6 months of age, every 3 months from 6 months to 2 years of age, and every 6 months from 2 years of age onward. Patients were eligible for enrollment if they had a documented sickle cell hemoglobinopathy (homozygous hemoglobin SS [HbSS], heterozygous hemoglobin SC [HbSC], heterozygous hemoglobin S thalassemia [HbS thal], or HbSS with high [ 20%] persistent fetal hemoglobin [Hb]) and if they were actively followed up in the sickle cell clinic at the Children s Hospital of Buffalo ( 1 clinic visit in the preceding year). Patients were excluded if they had consumed antibiotics other than their penicillin prophylaxis in the 72 hours prior to enrollment or if they had a history of penicillin allergy. After informed consent was obtained, each patient was asked to provide a urine sample, which was immediately refrigerated at 4 C. Catheterized or bagged specimens were obtained when the patient failed to void spontaneously. Each urine sample was assayed by an established method (Micrococcus luteus with disk diffusion) that detects excreted penicillin up to 15 hours after each dose administration. 5,6 Compliance was defined as evidence of any zone of inhibited bacterial growth around the disk. In addition, a structured interview was performed at enrollment in which patients and/or their family were questioned about their recent compliance with penicillin prophylaxis. Additional demographic information was abstracted from the patients medical records, including age, sex, insurance status, and diagnostic code at discharge from the emergency department. Categorical variables were assessed by 2 analysis, and continuous variables were assessed by the Student t test. Statistical analysis was performed with the Statistical Program for the Social Sciences (SPSS Inc, Chicago, Ill). Significance was defined as P.05. This study was approved by the institutional review board of the Children s Hospital of Buffalo. were enrolled in the study. Two were subsequently excluded (1 because the urine specimen was mishandled and 1 because of a penicillin allergy), leaving 123 (77.3%) Table 1. Demographics of Eligible Patients (N=123)* Characteristic No. (%) Sex Male 61 (49.6) Female 62 (50.4) Recruitment site Clinic 74 (60.2) Emergency department 49 (39.8) Diagnosis Clinic visit for routine care 74 (60.2) VOC 23 (18.7) Fever 18 (14.6) Fever and VOC 3 (2.4) Other 5 (4.1) Insurance status Public 90 (73.2) Private 28 (22.8) None 5 (4.1) Hemoglobinopathy HbSS 60 (48.8) HbSC 31 (25.2) HbS thal 16 (13.0) HbSS-HPFH 13 (10.6) Indeterminate 3 (2.4) *VOC indicates vaso-occlusive crisis; HbSS, homozygous hemoglobin SS; HbSC, heterozygous hemoglobin SC; HbS thal, heterozygous hemoglobin S -thalassemia; and HPFH, high persistent fetal hemoglobin. HbSS with high ( 20%) persistent fetal hemoglobin. Infants younger than 6 months with high ( 80%) fetal hemoglobin and no hemoglobin A. eligible patients for analysis. These patients are described in Table 1. The mean±sd age of the patients was 9.0±6.1 years (range, years), which was significantly younger than that of the group of patients who were not enrolled or were excluded (12.5±5.9 years; P=.003). There were no significant differences between the 2 groups with regard to sex, underlying hemoglobinopathy, or insurance status. There were no significant differences between the patients enrolled in the clinic and those enrolled in the emergency department with regard to age, sex, underlying hemoglobinopathy, or insurance status. COMPLIANCE Overall, 53 of 123 patients (43.1%; 95% confidence interval, 31.3%-51.7%) were compliant with their penicillin prophylaxis at their first enrollment in the study (ie, their urine specimens yielded zones of inhibition with the M luteus assay). By comparison, 83 of 123 patients (67.5%; 95% confidence interval, 59.2%-75.8%) reported consuming 1 dose of penicillin within the prior 15 hours. Patients who reported taking 1 dose of penicillin within the prior 15 hours were significantly more likely to have penicillin in their urine than those who reported taking no doses of penicillin within the prior 15 hours (49/83 [59%] vs 3/39 [8%], respectively; P.001). One patient was unsure if he had taken a dose within 15 hours of enrollment. The mean±sd number of patients with measured compliance at initial enrollment were significantly younger than patients with measured noncompliance 275
3 100 Table 2. Compliance Status by Various Factors* % of Patients <5 (n=41) 5-9 (n=33) (n=23) 15 (n=26) Age, y Compliance with penicillin prophylaxis by age at study enrollment. (7.6±6.3 years vs 10.1±5.9 years, respectively; P=.03). In addition, compliance was significantly greater in patients younger than 5 years than in those older than 5 years (25/41 [61%] vs 28/82 [34%], respectively; P=.004). Compliance by age at enrollment is depicted in the Figure. Measured compliance at initial enrollment was significantly greater among patients with private insurance than among those with public insurance (17/28 [61%] vs 33/90 [37%], respectively; P=.02). Five patients had no insurance. Compliance was otherwise not significantly associated with sex, hemoglobinopathy (HbSS vs all others), recruitment site (emergency department vs sickle cell clinic), or chief complaint in the emergency department (fever vs vaso-occlusive crisis) (Table 2). An unselected subgroup of 51 patients (41.5%) was enrolled more than 1 time in the study (at distinct presentations to either the clinic or emergency department) and provided a total of 141 urine specimens (median, 2 specimens; range, 2-8 specimens). Of the patients who tested positive for penicillin in their urine at their initial enrollment, 15 (79.0%) tested negative on 1 or more subsequent urine specimens. Of the 32 patients whose urine specimen tested negative for penicillin at their initial enrollment, 21 (65.6%) tested negative on all subsequent urine specimens. One 17-year-old girl tested negative on 7 consecutive specimens over an 8-month period. BACTEREMIA Compliant (n=53) During the 10-month study period, there were 2 episodes of documented pneumococcal bacteremia among the 159 patients actively followed up in the sickle cell clinic. One episode occurred in a 16-year-old boy whose initial urine specimen contained no penicillin. The other episode occurred in a 10-month-old male infant whose mother admitted to not providing penicillin prophylaxis. Urine collected from this patient 3 weeks later demonstrated the presence of penicillin. These 2 episodes yield an adjusted rate for the 10-month period of the study of 1.5 episodes of bacteremia per 100 patient-years of observation overall, and a rate of 2.9 episodes of bacteremia per 100 patient-years of observation for those younger than 5 years of age. COMMENT Noncompliant (n=70) Age, mean±sd, y 7.6± ± Insurance Private 17 (61) 11 (39) Public 33 (37) 57 (63).02 Penicillin history Last dose 15 h 3 (8) 36 (92) Last dose 15 h 49 (59) 34 (41).001 Sex Male 30 (49) 31 (51) Female 23 (37) 39 (63).17 Hemoglobinopathy HbSS 25 (42) 35 (58) All others 27 (45) 33 (55).71 Recruitment site ED 20 (41) 29 (59) Clinic 33 (45) 41 (55).69 Chief complaint in ED Fever 11 (52) 10 (48) VOC 9 (39) 14 (61).38 *Except for age, all data are number (percentage). HbSS indicates homozygous hemoglobin SS; ED, emergency department; and VOC, vaso-occlusive crisis. Five patients had no insurance. One patient was unsure of last dose of penicillin. Underlying hemoglobinopathy was unclear in 3 patients. Five patients had complaints other than fever or VOC. Despite the structured clinic setting in which the group of patients in our study were managed, fewer than half (43.1%) were compliant with their recommended penicillin prophylaxis at the time of their initial enrollment. Because penicillin prophylaxis provides no immediate tangible benefits for patients with sickle cell disease, it provides little positive reinforcement for strict compliance. Yet noncompliance with any medical regimen with proven clinical efficacy puts patients at risk for poor outcome. 7 In our study, both episodes of pneumococcal bacteremia occurred in patients with measured noncompliance. Noncompliance is a pervasive problem in several other chronic pediatric conditions. Although measurements of compliance differ in each case, prior studies have documented levels of noncompliance with long-term medical regimens of 10% to 60% in pediatric patients with end-stage renal disease, chronic asthma, diabetes, tuberculosis, and cancer Given the experience with these chronic medical conditions, it is not surprising that compliance with penicillin prophylaxis in our population was so low. Three smaller studies of compliance with prophylaxis in patients with sickle cell disease yielded overall compliance results similar to ours. Pegelow et al 17 examined compliance in 20 patients using the M lutea disk diffusion method and found that 11 (55%) were compliant. Also using the M lutea method, Buchanan et al 18 P 276
4 collected multiple specimens from 37 patients and found that 87(64.4%) of 135 contained penicillin. Using a slightly different urine assay, Cummins et al 19 reported penicillin in 10 (44%) of 23 urine specimens tested. As in our study, they noted a striking disparity between reported compliance (62%) and actual measured compliance (44%). Our study is superior to each of these prior efforts because we studied a larger group of patients and extended the analysis by identifying subgroups with high and low compliance. One group with significantly greater compliance was patients younger than 5 years. Because these patients are at highest risk for bacteremia, they therefore have the most to benefit from prophylaxis. Compliance may be higher in this age group because patients younger than 5 years receive their prophylaxis from their parents as opposed to taking it themselves. Alternatively, staff in the clinic may emphasize compliance more strongly in younger patients because of their known higher risk for bacteremia. New education efforts in the clinic setting may help parents understand that compliance may decrease as they begin to rely on their children to take their own medication. If the practitioner decides to continue penicillin prophylaxis beyond 5 years of age, supervised dispensing of the drug by parents should be recommended for as long as possible. In addition, the practitioner should counsel both the family and the older child on the importance of continued compliance. We also identified public insurance as a risk factor for noncompliance. The reasons are unclear. Patients were seen routinely in the clinic and the emergency department without regard to their insurance status. There were neither different facilities nor different approaches to care for patients with public insurance. In New York State, prescriptions for penicillin are covered by Medicaid for periods up to 6 months (in 1-month renewal aliquots). Private insurers are more restrictive, often requiring special exemption letters from physicians to allow longterm medications. Thus, restricted access does not explain the noncompliance among the public insurance sector. Last, we have no evidence that patients receiving public insurance were older, attended the clinic less frequently, or were less educated or otherwise less able to understand the importance of compliance. Our data are limited because, for the majority of patients, we only measured compliance at one point in time. We did assess compliance longitudinally in the unselected subgroup of 51 patients who provided more than 1 urine specimen at distinct times. Most of the patients whose specimens tested negative initially had subsequent specimens that tested negative (21/32 [66%]), and most of the patients whose specimens tested positive initially had 1 subsequent negative specimen (15/19 [79%]). In other words, patients who were noncompliant at enrollment tended to remain noncompliant, and patients who were compliant at enrollment were often subsequently noncompliant. The poor compliance in our population raises the question of why the incidence of pneumococcal bacteremia was so low. Although the rate of pneumococcal bacteremia in our study for patients younger than 5 years, 2.9 episodes per 100 patient-years, was higher than the rate in the intervention group (patients 4 years of age) of the Prophylactic Penicillin Study (PROPS), episodes per 100 patient-years, both rates are much lower than the 9.8 episodes per 100 patientyears observed in the PROPS placebo group. Assuming that compliance in the PROPS approximated that of ours, why were the rates of pneumococcal bacteremia among the patients receiving prophylaxis in both studies so low? Several answers are possible. First, clearly the population that benefits the most from prophylaxis, those younger than 5 years of age, are receiving it the most frequently. Second, it could be that the rate of infection among the placebo group in the PROPS was unexpectedly high. This seems unlikely, as rates of pneumococcal bacteremia prior to the introduction of penicillin prophylaxis ranged from 5.8 to 11.6 episodes per 100 patient-years. 20,21 Pneumococcal vaccination with the polysaccharide vaccine has probably done little to alter these rates, given the poor response to vaccination among patients with sickle cell disease demonstrated in the recent report by Bjornson et al. 22 Third, it could be that prophylaxis decreases nasopharyngeal carriage of S pneumoniae. Recent data from Philadelphia, Pa, 23 and Memphis, Tenn, 24 however, demonstrate that 10% to 13% of their populations showed colonization, and in the series from Philadelphia, 23 colonization did not differ between those receiving and not receiving prophylaxis. Finally, it could be that parents are starting prophylaxis when their children develop fevers, thus attenuating early pneumococcal bacteremia. Our data do not support this idea, as we found no difference in compliance between patients presenting to the emergency department with and without fevers. In conclusion, we have demonstrated poor compliance with recommended penicillin prophylaxis against spontaneous pneumococcal bacteremia in a closely managed population of patients with sickle cell disease. Children older than 5 years and children covered by public insurance are at risk for particularly poor compliance. Our data suggest that efforts are necessary to improve compliance in all groups through vigorous medical and social service intervention. Such an effort merits further study. Accepted for publication September 29, Presented at the annual meeting of the Ambulatory Pediatric Association, Washington, DC, May 2, Corresponding author: Stephen J. Teach, MD, MPH, Emergency Medical Trauma Center, Children s National Medical Center, Suite 1450, 111 Michigan Ave NW, Washington, DC ( steach@cnmc.org). REFERENCES 1. Robinson MG, Watson RJ. Pneumococcal meningitis in sickle cell anemia. N Engl J Med. 1966;274: Gaston MH, Verter JI, Woods G, et al. Prophylaxis with oral penicillin in children with sickle cell anemia. N Engl J Med. 1986;314: Committee on Genetics. Health supervision for children with sickle cell disease and their families. Pediatrics. 1996;98:
5 4. Falleta JM, Woods GM, Verter JI, et al. Discontinuing penicillin prophylaxis in children with sickle cell anemia. J Pediatr. 1995;127: Charney E, Bynum R, Eldredge D, et al. How well do patients take oral penicillin? Pediatrics. 1967;40: Markowitz M, Gordis L. A mail-in technique for detecting penicillin in urine: application to the study of maintenance of prophylaxis in rheumatic fever patients. Pediatrics. 1968;41: Lilleyman JS, Lennard L. Non-compliance with oral chemotherapy in childhood leukemia: an overlooked and costly cause of late relapse. BMJ. 1996;313: Tebbi CK. Treatment compliance in childhood and adolescence. Cancer. 1993; 71: Tebbi CK, Cummings KM, Zevon MA, et al. Compliance of pediatric and adolescent cancer patients. Cancer. 1986;58: Brownridge G, Fielding DM. Psychosocial adjustment and adherence to dialysis treatment regimens. Pediatr Nephrol. 1994;8: Johnson SB, Silverstein J, Rosenbloom A, et al. Assessing daily management in childhood diabetes. Health Psychol. 1986;5: Sublett JL, Pollard SJ, Kadlec GJ, et al. Non-compliance in asthmatic children: a study of theophylline levels in a pediatric emergency room population. Ann Allergy. 1979;43: Eney RD, Goldstein EO. Compliance of chronic asthmatics with oral administration of theophylline as measured by serum and salivary levels. Pediatrics. 1976; 57: Hudson J, Fielding D, Jones S, et al. Adherence to medical regime and related factors in youngsters on dialysis. Br J Clin Psychol. 1987;26: Byers N. Delay in the diagnosis, notification, and initiation of treatment and compliance in children with tuberculosis. Tuber Lung Dis. 1994;75: Gibson NA. Compliance with inhaled asthma medication in pre-school children. Thorax. 1995;50: Pegelow CH, Armstrong FD, Light S, Toledano SR, Davis J. Experience with the use of prophylactic penicillin in children with sickle cell anemia. J Pediatr. 1991; 118: Buchanan GR, Siegel JD, Smith SJ, DePasse BM. Oral penicillin prophylaxis in children with impaired splenic function: a study of compliance. Pediatrics. 1982; 70: Cummins D, Heuschkel R, Davies SC. Penicillin prophylaxis in children with sickle cell disease in Brest. BMJ. 1991;302: Overturf GD, Powars D, Baraff LJ. Bacterial meningitis and septicemia in sickle cell disease. AJDC. 1977;131: Powars D, Overturf GD, Weiss J, Lee S, Chan L. Pneumococcal septicemia in children with sickle cell anemia: a changing trend of survival. JAMA. 1981;245: Bjornson AB, Falletta JM, Verter JI, et al. Serotype-specific immunoglobulin G antibody responses to pneumococcal polysaccharide vaccine in children with sickle cell anemia: effects of continued penicillin prophylaxis. J Pediatr. 1996;129: Norris CF, Mahannah SR, Smith-Whitley K, Ohene-Frempong K, McGowan KL. Pneumococcal colonization in children with sickle cell disease. J Pediatr. 1996; 129: Daw NC, Wilimas JA, Wang WC, et al. Nasopharyngeal carriage of penicillinresistant Streptococcus pneumoniae in children with sickle cell disease. Pediatrics. 1997;99:595. Correction Misspelling of Surname and Word in Reprint Address. In the Picture of the Month published in the December issue of the ARCHIVES (1997;151: ) Dr Yasemen Eroǵlu s surname was misspelled in the table of contents, byline, affiliation footnote, and reprint address. Also the word Mithatpaşa- was misspelled in the reprint address. Both misspellings were caused by a deficiency in the electronic conversion program. The journal apologizes for the error. 278
MI Newborn Screening Program: An Overview of Follow-up & Case Management for Sickle Cell Conditions
Michigan Department of Community Health MI Newborn Screening Program: An Overview of Follow-up & Case Management for Sickle Cell Conditions Dominic Smith, MSA - Linda Carter, BSW - Ben Frazier, BSW - Ruth
More informationOriginal Research Article Ssafety and efficacy of prolonged hydroxycarbamide administration in adults with
1 1 2 3 Original Research Article Ssafety and efficacy of prolonged hydroxycarbamide administration in adults with sickle cell disease in Northwestern Greece 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20
More informationDescription of the evidence collection method. (1). Each recommendation was discussed by the committee and a consensus
Special Article Guidelines on the treatment of primary immune thrombocytopenia in children and adolescents: Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular Sandra Regina Loggetto 1
More informationBacteremia Risk and Outpatient Management of Febrile Patients With Sickle Cell Disease
ARTICLE Bacteremia Risk and Outpatient Management of Febrile Patients With Sickle Cell Disease AUTHORS: Marc N. Baskin, MD, a,b Xin Lyn Goh, BMedSc, c Matthew M. Heeney, MD, b,d and Marvin B. Harper, MD
More informationA bout 170 babies are born annually in the UK with sickle
325 Coping and health service utilisation in a UK study of paediatric sickle cell pain K A Anie, A Steptoe, S Ball, M Dick, B M Smalling... Seeletteronp385 See end of article for authors affiliations...
More informationIf these vaccines haven t been given, please follow guidelines below for emergency procedures.
MANAGEMENT OF PATIIENTS POST SPLENECTOMY & HYPOSPLENIIC PATIIENTS Splenectomised and hyposplenic patients are at increased risk of life-threatening infections due to encapsulated micro-organisms such as
More informationInstructor s Manual Chapter 26 Hematological Alterations. 1. A man and woman both test positive for the sickle cell trait. The couple asks the
1 Instructor s Manual Chapter 26 Hematological Alterations Answers to Study Questions 1. A man and woman both test positive for the sickle cell trait. The couple asks the nurse how many of their children
More informationABSTRACT. Background: Newborn screening (NBS) for hemoglobinopathies is an effective first step to reduce
ABSTRACT Background: Newborn screening (NBS) for hemoglobinopathies is an effective first step to reduce morbidity and mortality of all affected newborns. The screening allows early detection and intervention
More informationHydroxyurea. for Sickle Cell Disease. A Guide for Starting Treatment. Hydroxyurea is a medicine proven to prevent pain from sickle cell disease.
Hydroxyurea for Sickle Cell Disease A Guide for Starting Treatment Hydroxyurea is a medicine proven to prevent pain from sickle cell disease. This handbook was created to help answer common questions about
More informationNewborn Screening for Sickle Cell Disease in Africa: Public health meets reality
13 th September 2016 Newborn Screening for Sickle Cell Disease in Africa: Public health meets reality Kwaku Ohene-Frempong. MD Children s Hospital of Philadelphia Sickle Cell Foundation of Ghana Disclosure
More informationNewborn Screening for Sickle Cell Disease in Ghana Update
National Programme of Newborn Screening for Sickle Cell Disease Newborn Screening for Sickle Cell Disease in Ghana ---------- Update Prof. Kwaku Ohene-Frempong, MD Children s Hospital of Philadelphia University
More informationSickle Cell Disease. Edward Malters, MD
Sickle Cell Disease Edward Malters, MD Introduction Vaso-occlusive phenomena and hemolysis are the clinical hallmarks of Sickle Cell Disease (SCD) Inherited disorder due to homozygosity for the abnormal
More informationThe National Asthma Education and Prevention Program s
Long-Acting b-agonist Among Children and Adults With Asthma Elizabeth A. Wasilevich, PhD, MPH; Sarah J. Clark, MPH; Lisa M. Cohn, MS; and Kevin J. Dombkowski, DrPH Managed Care & Healthcare Communications,
More informationInvasive Bacterial Disease
Invasive Bacterial Disease All Streptococcus pneumoniae Electronic Disease Surveillance System Division of Surveillance and Disease Control Infectious Disease Epidemiology Program : 304-558-5358 or 800-423-1271
More informationBridging the Gap: Improving Sickle Cell Disease Transition from Pediatric- to Adult-Focused Care ASFA 2017 Annual Meeting
Bridging the Gap: Improving Sickle Cell Disease Transition from Pediatric- to Adult-Focused Care ASFA 2017 Annual Meeting Kim Smith-Whitley, MD Director Comprehensive Sickle Cell Center The Children s
More informationComprehensive Care for Children and Adolescents with Sickle Cell Diseases
Comprehensive Care for Children and Adolescents with Sickle Cell Diseases Objectives To review the system for newborn screening of infants for sickling diseases To provide the framework for a comprehensive
More informationStreptococcus Pneumoniae
Streptococcus Pneumoniae (Invasive Pneumococcal Disease) DISEASE REPORTABLE WITHIN 24 HOURS OF DIAGNOSIS Per N.J.A.C. 8:57, healthcare providers and administrators shall report by mail or by electronic
More informationNewborn Screening and Followup for Hemoglobinopathies
Newborn Screening and Followup for Hemoglobinopathies October 4, 2012 Monica Hulbert, MD Director, Sickle Cell Disease Program Washington University School of Medicine St. Louis Children s Hospital Disclosures
More informationHigh Hemoglobin F in a Saudi Child Presenting with Pancytopenia
Case Report imedpub Journals http://www.imedpub.com Journal of Pediatric Care ISSN 2471-805X DOI: 10.21767/2471-805X.100002 High Hemoglobin F in a Saudi Child Presenting with Pancytopenia Abstract Saudi
More informationHydroxyurea and Transfusion Therapy for the Treatment of Sickle Cell Disease
Hydroxyurea and Transfusion Therapy for the Treatment of Sickle Cell Disease A Pocket Guide for the Clinician Susan E. Creary, MD, MSc 1 John J. Strouse, MD, PhD 2 1 The Ohio State University School of
More informationFever in the Newborn Period
Fever in the Newborn Period 1. Definitions 1 2. Overview 1 3. History and Physical Examination 2 4. Fever in Infants Less than 3 Months Old 2 a. Table 1: Rochester criteria for low risk infants 3 5. Fever
More informationAlberta Health and Wellness Public Health Notifiable Disease Management Guidelines August Pneumococcal Disease, Invasive (IPD)
August 2011 Pneumococcal Disease, Invasive (IPD) Revision Dates Case Definition Reporting Requirements Remainder of the Guideline (i.e., Etiology to References sections inclusive) Case Definition August
More informationIncidence per 100,000
Streptococcus pneumoniae Surveillance Report 2005 Oregon Active Bacterial Core Surveillance (ABCs) Office of Disease Prevention & Epidemiology Oregon Department of Human Services Updated: March 2007 Background
More information3. FEVER. Principles. Recommendations. Education of Patients, Families and Caregivers. Triage and Initial Management
3. FEVER Principles Infection is the most common cause of sickle cell disease-related mortality. Febrile patients with sickle cell disease should be managed promptly to prevent serious infectious complications.
More informationStreptococcus pneumoniae CDC
Streptococcus pneumoniae CDC Pneumococcal Disease Infection caused by the bacteria, Streptococcus pneumoniae» otitis media 20 million office visits (28-55% Strep)» pneumonia 175,000 cases annually» meningitis
More informationAtlantic Provinces Pediatric Hematology Oncology Network Réseau d Oncologie et Hématologie Pédiatrique des Provinces Atlantiques
Atlantic Provinces Pediatric Hematology Oncology Network Réseau d Oncologie et Hématologie Pédiatrique des Provinces Atlantiques 5850/5980 University Avenue, PO Box 9700 Halifax, NS, B3K 6R8 1.902.470.7429
More informationAPEC Guidelines Immunizations
Pregnancy provides an excellent opportunity to enhance a woman s protection against disease and to provide protection to the neonate during the first 3 to 6 months of life. Women of childbearing age should
More informationAppendix A: Disease-Specific Chapters
Ministry of Health and Long-Term Care Infectious Diseases Protocol Appendix A: Disease-Specific Chapters Chapter: Haemophilus influenzae disease, all types, invasive Effective: May 2018 Haemophilus influenzae,
More informationNEWBORN SCREENING FOR SICKLE CELL DISEASE Progress Towards Improved Outcomes for Children and Families
NEWBORN SCREENING FOR SICKLE CELL DISEASE Progress Towards Improved Outcomes for Children and Families Peter A. Lane, MD Department of Pediatrics Emory University School of Medicine Atlanta, GA U.S. NEONATAL
More informationDAYTON CHILDREN S HOSPITAL CLINICAL PRACTICE GUIDELINES
DAYTON CHILDREN S HOSPITAL CLINICAL PRACTICE GUIDELINES DISCLAIMER: This Clinical Practice Guideline (CPG) generally describes a recommended course of treatment for patients with the identified health
More informationTB Clinical Guidelines: Revision Highlights March 2014
TB Clinical Guidelines: Revision Highlights March 2014 AIR TRAVEL & TB CONTROL With respect to non-ambulance air travel of patients diagnosed with or suspected as having active Mycobacterium tuberculosis,
More informationSickle cell disease (SCD) is a genetic disorder characterized
Assessment of Personal Medical History Knowledge in Adolescents with Sickle Cell Disease: A Pilot Study Mimi S. Zhao, MA, Margery Johnson, LCSW, Amanda Pullen, MSSW, LCSW, Kathryn M. Russell, PhD, Kimberly
More informationPneumococcal vaccines
Pneumococcal vaccines Marco Aurélio Sáfadi, MD, PhD FCM da Santa Casa de São Paulo Challenges in establishing the baseline burden of disease, before implementing a vaccination program S. pneumoniae disease
More informationDoes This Child Have a Urinary Tract Infection?
EVIDENCE-BASED EMERGENCY MEDICINE/RATIONAL CLINICAL EXAMINATION ABSTRACT Does This Child Have a Urinary Tract Infection? EBEM Commentator Contact Rupinder Singh Sahsi, BSc, MD Christopher R. Carpenter,
More informationSickle Cell Service to Humanity Foundation, Katsina State, Nigeria: Exploratory Visit
Sickle Cell Service to Humanity Foundation, Katsina State, Nigeria: Exploratory Visit Nigerian Sickle Cell Cohort Team, UNDP N-253 project contact (+2348036063948) Dr Baba Inusa (Chief Investigator) Dr
More information1 Kattamis et al. Growth of Children with Thalassemia: Effect of Different Transfusion Regimens. Archives of
Objectives Sickle Cell Anemia and Thalassemia: Transplantation Provide overview of hemoglobinopathies: Sickle cell disease and Thalassemia Discuss approaches to therapy Review recent registry collaboration
More informationHow to Write a Life Care Plan for a Child with Hemoglobinopathy
How to Write a Life Care Plan for a Child with Hemoglobinopathy Tamar Fleischer, BSN, MSN, CNLCP & Mona Yudkoff, RN, MPH, CRRN, CNLCP BalaCare Solutions March 2018 St. Peterburg, Florida What is Hemoglobinopathy?
More informationFever Interval before Diagnosis, Prior Antibiotic Treatment, and Clinical Outcome for Young Children with Bacterial Meningitis
MAJOR ARTICLE Fever Interval before Diagnosis, Prior Antibiotic Treatment, and Clinical Outcome for Young Children with Bacterial Meningitis Bema K. Bonsu 1 and Marvin B. Harper 2 1 Department of Medicine,
More informationRoutine Adult Immunization: American College of Preventive Medicine Practice Policy Statement, updated 2002
Routine Adult Immunization: American College of Preventive Medicine Practice Policy Statement, updated 2002 Ann R. Fingar, MD, MPH, and Byron J. Francis, MD, MPH Burden of suffering Vaccines are available
More informationNORTHEAST HOSPITAL CORPORATION
NORTHEAST HOSPITAL CORPORATION Title: Influenza and Pneumococcal Immunization Date Effective: 11/04 Date Revised: 7/08, 2/6/12, 3/15/13; 9/13/13 Date Reviewed: Joint Commission Chapter: Provision of Care,
More informationOverview of Newborn Screening, Potential Uses of Residual Dried Blood Spots, and Protection of Privacy
Overview of Newborn Screening, Potential Uses of Residual Dried Blood Spots, and Protection of Privacy Alan R. Fleischman, M.D. Senior Vice President and Medical Director Chair, Federal Advisory Committee,
More informationEarly and Periodic Screening, Diagnosis and Treatment (EPSDT)
Early and Periodic Screening, Diagnosis and Treatment (EPSDT) EPSDT and Bright Futures: Michigan MICHIGAN (MI) Medicaid s EPSDT benefit provides comprehensive health care services to children under age
More informationMyths and beliefs of long-term care providers towards starting inhaled medications in children with bronchial asthma
and beliefs of long-term care providers towards starting inhaled medications in children with bronchial asthma *N A W K Nettikumara 1, K A M K U N Malaviarachchi 2, Y C N Dissanayaka 3, U C Gunarathna
More informationPerformance Improvement Projects Related to CDC s 6 18 Initiative: A Scan of External Quality Review Organization Reports
Technical Assistance Tool June 2018 Performance Improvement Projects Related to CDC s 6 18 Initiative: A Scan of External Quality Review Organization Reports S tates implementing interventions under CDC
More informationRecommended Childhood Immunization Schedu...ates, January - December 2000, NP Central
Recommended Childhood Immunization Schedule United States, January - December 2000 Vaccines 1 are listed under routinely recommended ages. Solid-colored bars indicate range of recommended ages for immunization.
More informationPersistence of Immunity to Live Attenuated Varicella Vaccine in Healthy Adults
MAJOR ARTICLE Persistence of Immunity to Live Attenuated Varicella Vaccine in Healthy Adults Krow Ampofo, 1 Lisa Saiman, 1,2 Philip LaRussa, 1 Sharon Steinberg, 1 Paula Annunziato, 1 and Anne Gershon 1
More informationGroup B Streptococcus
Group B Streptococcus (Invasive Disease) Infants Younger than 90 Days Old DISEASE REPORTABLE WITHIN 24 HOURS OF DIAGNOSIS Per N.J.A.C. 8:57, healthcare providers and administrators shall report by mail
More informationAnemia s. Troy Lund MSMS PhD MD
Anemia s Troy Lund MSMS PhD MD lundx072@umn.edu Hemoglobinopathy/Anemia IOM take home points. 1. How do we identify the condtion? Smear, CBC Solubility Test (SCD) 2. How does it present clincally? 3. How
More information2. RESPONSIBLE PARTIES:
Retired Date: Page 1 of 6 1. POLICY: Exchange Transfusion for Sickle Cell 2. RESPONSIBLE PARTIES: Medical Management Administration, Utilization Management, Integrated Care Management, Claims Department,
More informationWhy is the management of UTI so controversial? Kjell Tullus Consultant Paediatric Nephrologist
Why is the management of UTI so controversial? Kjell Tullus Consultant Paediatric Nephrologist Diagnosing a UTI More difficult then most people realise Contaminating culture Bacterial numbers Confusion
More informationInvasive Bacterial Disease
Invasive Bacterial Disease Neisseria meningitidis, Haemophilus influenzae, and Group B Streptococcus (Streptococcus agalactiae) Case Report Form Electronic Disease Surveillance System Division of Surveillance
More informationHealth Maintenance and Education for Children and Adults
Health Maintenance and Education for Children and Adults Richard Ward, MSc, MRCP, FRCPath Director, Red Blood Cell Disorders Program, UHN Assistant Professor, Hematology, University of Toronto Chair, Canadian
More informationAsyntomatic bacteriuria, Urinary Tract Infection
Asyntomatic bacteriuria, Urinary Tract Infection C. Infectious Diseases Society of America Guidelines for the Diagnosis and Treatment of Asyntomatic Bacteriuria in Adults (2005) Pyuria accompanying asymptomatic
More informationParental Perception of Quality of Hospital Care for Children with Sickle Cell Disease
Parental Perception of Quality of Hospital Care for Children with Sickle Cell Disease Jared Kam, BS; Julie A. Panepinto, MD, MSPH; Amanda M. Brandow, DO; David C. Brousseau, MD, MS Abstract Problem Considered:
More informationMental and Physical Health of Youth in Clinical and Community Settings
Mental and Physical Health of Youth in Clinical and Community Settings Teresa L. Kramer, Ph.D. Martha M. Phillips, Ph.D. Terri L. Miller, Ph.D. Relationships Between Depression and Obesity in Adolescents
More informationFamily Centered Pediatric Emergency Department Sickle Cell Assessment of Needs and Strengths (FC-Peds-ED-SCANS) Overall Algorithm
Family Centered Pediatric Emergency Department Sickle Cell Assessment of Needs and Strengths (FC-Peds-ED-SCANS) Overall Algorithm Decision 1: Triage Decision 2: Analgesic Management Decision 3: Diagnostic
More informationproposed set to a required subset of 3 to 5 measures based on the availability of electronic
CMS-0033-P 143 proposed set to a required subset of 3 to 5 measures based on the availability of electronic measure specifications and comments received. We propose to require for 2011 and 2012 that EP's
More informationRisk profiles and vaccine uptake in children with invasive pneumococcal disease at a tertiary hospital in Tshwane:
Risk profiles and vaccine uptake in children with invasive pneumococcal disease at a tertiary hospital in Tshwane: A retrospective review Xandré Dearden www.up.ac.za IPD: disease spectrum and epidemiology
More informationInvestigation of a Neisseria meningitidis Serogroup A Case in the Meningitis Belt. January 2017
January 2017 Investigation of a Neisseria meningitidis Serogroup A Case in the Meningitis Belt Introduction Since the progressive introduction of meningococcal serogroup A conjugate vaccine (MACV) in the
More informationARTICLE. Differentiating Osteomyelitis From Vaso-occlusive Crisis. Elizabeth Berger, MD; Natasha Saunders, MD; Lisa Wang, MSc; Jeremy N.
ARTICLE Sickle Cell Disease in Children Differentiating Osteomyelitis From Vaso-occlusive Crisis Elizabeth Berger, MD; Natasha Saunders, MD; Lisa Wang, MSc; Jeremy N. Friedman, MD Objective: To identify
More informationProject TEACH Addressing Tobacco Treatment for Pregnant Women Jan Blalock, Ph.D.
Project TEACH Addressing Tobacco Treatment for Pregnant Women Jan Blalock, Ph.D. Prevalence of Smoking and Cessation During Pregnancy In 2014, 14% in women with Medicaid coverage versus 3.6% of women with
More informationSickle Cell Disease Integrated Care Models: Outpatient and Inpatient National Minority Quality Forum April 2017
Sickle Cell Disease Integrated Care Models: Outpatient and Inpatient National Minority Quality Forum April 2017 Kim Smith-Whitley, MD Director Comprehensive Sickle Cell Center The Children s Hospital of
More informationReference ID:
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use ENDARI TM safely and effectively. See full prescribing information for ENDARI. ENDARI (L-glutamine
More informationCurrent Status of PCV Use and WHO Recommendations
Current Status of PCV Use and WHO Recommendations SAGE 18 October 2017 Kate O Brien, MD MPH 1 Pneumonia remains a major cause of child deaths LMIC LMIC Pneumonia HIC HIC Pneumonia ~16% ~5% 2015 Black,
More informationOf 142 cases where sex was known, 56 percent were male; of 127cases where race was known, 90 percent were white, 4 percent were
Group B Streptococcus Surveillance Report 2014 Oregon Active Bacterial Core Surveillance (ABCs) Center for Public Health Practice Updated: November 2015 Background The Active Bacterial Core surveillance
More informationEPIREVIEW INVASIVE PNEUMOCOCCAL DISEASE, NSW, 2002
EPIREVIEW INVASIVE PNEUMOCOCCAL DISEASE, NSW, 2002 Robyn Gilmour Communicable Diseases Branch NSW Department of Health BACKGROUND Infection with the bacterium Streptococcus pneumoniae is a major cause
More informationSickle Cell Disease Why Is A Simple Genetic Disorder So Hard To Treat And How Are We Doing?
Sickle Cell Disease Why Is A Simple Genetic Disorder So Hard To Treat And How Are We Doing? James R. Eckman, MD Professor of Medicine, Hematology and Oncology Winship Cancer Institute Emory University
More informationThird Visit Posttest
Test code 03C Patient s name: Third Visit Posttest Patient s birth date: Your name and relationship to patient: Today s date: Please mark only one answer for each of the following questions: 1. Which one
More informationDECISION SUPPORT TOOL FOR RN SANES DISPENSING PROPHYLAXIS FOR SEXUALLY TRANSMITTED INFECTION AFTER SEXUAL ASSAULT
BC WOMEN S SEXUAL ASSAULT SERVICE PURPOSE DECISION SUPPORT TOOL FOR RN SANES DISPENSING PROPHYLAXIS FOR SEXUALLY TRANSMITTED INFECTION AFTER SEXUAL ASSAULT This decision support tool (DST) and accompanying
More informationUTI and VUR Practical points and management Kjell Tullus Consultant Paediatric Nephrologist
UTI and VUR Practical points and management Kjell Tullus Consultant Paediatric Nephrologist Discussion points Diagnosis VUR Radiological investigations 1. Contamination Problems 2. Bacterial numbers 3.
More informationGuidelines for management of suspected sepsis in young infants where referral is not possible
Guidelines for management of suspected sepsis in young infants where referral is not possible Kenya Paediatrics Association Conference, 26-29 April 2016, Eldoret Kenya 1 Kenya Paediatrics Association Conference,
More informationMedical Care Utilization and Mortality in Sickle Cell Disease: A Population-Based Study
American Journal of Hematology 80:262 270 (2005) Medical Care Utilization and Mortality in Sickle Cell Disease: A Population-Based Study Sadhna M. Shankar, 1,5 * Patrick G. Arbogast, 3 Ed Mitchel, 4,6,7,8,9
More informationFever in Babies. Too much testing or not enough testing? Martin E. Weisse, M.D. Pediatric Infectious Diseases
Fever in Babies Too much testing or not enough testing? Martin E. Weisse, M.D. Pediatric Infectious Diseases Disclosures I have nothing to disclose Learning Objectives At the end of the talk, participants
More information3 rd dose. 3 rd or 4 th dose, see footnote 5. see footnote 13. for certain high-risk groups
Figure 1. Recommended immunization schedule for persons aged 0 through 18 years 2013. (FOR THOSE WHO FALL BEHIND OR START LATE, SEE THE CATCH-UP SCHEDULE [FIGURE 2]). These recommendations must be read
More informationMicrobiology Laboratory Directors, Infection Preventionists, Primary Care Providers, Emergency Department Directors, Infectious Disease Physicians
MEMORANDUM DATE: October 1, 2009 TO: FROM: SUBJECT: Microbiology Laboratory Directors, Infection Preventionists, Primary Care Providers, Emergency Department Directors, Infectious Disease Physicians Michael
More informationNOTE: The above recommendations must be read along with the footnotes of this schedule.
Figure 1. Recommended immunization schedule for persons aged 0 through 18 years United States, 2014. (FOR THOSE WHO FALL BEHIND OR START LATE, SEE THE CATCH-UP SCHEDULE [FIGURE 2]). These recommendations
More informationShould blood cultures be obtained in all infants 3 to 36 months presenting with significant fever? abstract CLINICAL QUESTION REVIEW
CLINICAL QUESTION REVIEW CQR is a recurring section in Hospital Pediatrics where authors start with a relevant clinical question, find and synthesize the recent literature and provide their best answer
More informationHOW DO VACCINES WORK?
Official Topic from UpToDate, the clinical decision support resource accessed by 700,000+ clinicians worldwide. Available via the web and mobile devices, subscribe to UpToDate at www.uptodate.com/store.
More information1. Adequate diet and iron intake to prevent iron deficiency 2. Signs and symptoms of malignant disease
Hematology/Oncology Description: The pediatric hematology-oncology division sees a wide spectrum of pediatric disease including but not limited to leukemia, hemophilia, solid tumors, ITP, and other blood
More informationPEDIATRIC HEMATOLOGY/ONCOLOGY ROTATION
DEPARTMENT OF PEDIATRICS NATIONAL CAPITAL CONSORTIUM PEDIATRIC RESIDENCY PROGRAM PEDIATRIC HEMATOLOGY/ONCOLOGY ROTATION February 2017 1. DURATION OF ROTATION: One (1) block/four (4) weeks. 2. ELIGIBILITY:
More informationRelationship of Socioeconomic Status with Exacerbation Frequency among Children with Asthma in Malaysia
1st Public Health International Conference (PHICo 2016) Relationship of Socioeconomic Status with Exacerbation Frequency among Children with Asthma in Malaysia Aniza Ismail1, Nurmawati Ahmad2, Saperi Sulong3,
More informationChristine A. Bono, PhD Program Associate. Elizabeth Shenkman, PhD Principal Investigator. October 24, 2003
COMPARING HEALTH CARE OUTCOMES FOR CHILDREN ENROLLED IN THE FLORIDA HEALTHY KIDS PROGRAM AND CARED FOR BY PEDIATRICIANS VS. FAMILY PRACTITIONERS A REPORT PREPARED FOR THE HEALTHY KIDS BOARD OF DIRECTORS
More informationInfluenza Therapies. Considerations Prescription influenza therapies require prior authorization through pharmacy services.
Influenza Therapies Policy Number: 5.01.515 Last Review: 10/2017 Origination: 10/2002 Next Review: 10/2018 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide coverage for influenza
More informationHematology/Oncology/BMT
The University of Arizona Pediatric Residency Program Primary Goals for Rotation Hematology/Oncology/BMT 1. GOAL: Understand the role of the pediatrician in preventing hematologic or oncologic conditions,
More informationA scoring system for the effectiveness of Hepatitis-B vaccination in children receiving treatment for cancer
Turkish Journal of Cancer Vol.3/ No. 4/2 A scoring system for the effectiveness of Hepatitis-B vaccination in children receiving treatment for cancer FUNDA ÇORAPÇIOĞLU, FAİK SARIALİOĞLU, NUR OLGUN, KAMER
More informationVaccination Programs: Client-Held Paper Immunization Records
Vaccination Programs: Client-Held Paper Immunization Records Summary Evidence Table Updated Evidence (search period: 1980-February 2012) population, Setting, Dickey (1992) Period: 1988-1989 Greatest (Group
More informationJuly, Years α : 7.7 / 10, Years α : 11 / 10,000 < 5 Years: 80 / 10, Reduce emergency department visits for asthma.
What are the Healthy People 1 objectives? July, 6 Sponsored by the U.S. Department of Health and Human Services, the Healthy People 1 initiative is a comprehensive set of disease prevention and health
More informationBCG vaccine and tuberculosis
PART 2: Vaccination for special risk groups 2.1 Vaccination for Aboriginal and Torres Strait Islander people Aboriginal and Torres Strait Islander people historically had a very high burden of infectious
More informationIndividuals with psychiatric illnesses represent a significant
CLINICAL INVESTIGATIONS Emergency Medicine and Psychiatry Agreement on Diagnosis and Disposition of Emergency Department Patients With Behavioral Emergencies Amy M. Douglass, John Luo, MD and Larry J.
More information11/17/2013 THE WHO, WHAT, WHEN, AND WHY OF ADULT VACCINATIONS. Pneumococcal Vaccines for Adults (PPV) Pneumococcal Vaccines
THE WHO, WHAT, WHEN, AND WHY OF ADULT VACCINATIONS CAROL A. KAUFFMAN, MD VA ANN ARBOR HEALTHCARE SYSTEM UNIVERSITY OF MICHIGAN Will discuss: bacterial vaccines made of toxoids or polysaccharide capsular
More informationSickle Cell Disease an Overview
Sickle Cell Disease an Overview 11 th Annual Sickle Cell Disease and Thalassemia Conference 11 October 2017 Winfred Wang, MD St. Jude Children s Research Hospital Memphis, TN, USA Outline of Overview Sickle
More informationReligion, Reproductive Health and Access to Services: A National Survey of Women. Conducted for Catholics for a Free Choice
RESEARCH AND COMMUNICATIONS Religion, Reproductive Health and Access to Services: A National Survey of Women Conducted for Catholics for a Free Choice by Belden Russonello & Stewart April 2000 1320 19TH
More informationNil /able data reported on the frequency
This is a description of mortality and morbidity in infants and preschool children in Minneapolis. After presenting the findings, the authors discuss how such data can be used for program planning and
More informationVaccinated versus Unvaccinated Children and Chronic Disease. Chronic health conditions are being reported in more than half of American
Vaccinated versus Unvaccinated Children and Chronic Disease Chronic health conditions are being reported in more than half of American schoolchildren, (1.) with conditions such as allergies, learning and
More informationARTICLE. Clinical Decision Rule to Identify Febrile Young Girls at Risk for Urinary Tract Infection
Clinical Decision Rule to Identify Febrile Young Girls at Risk for Urinary Tract Infection Marc H. Gorelick, MD, MSCE; Kathy N. Shaw, MD, MSCE ARTICLE Objective: To develop a clinical prediction rule to
More informationMaternal and Infant Nutrition Briefs
Maternal and Infant Nutrition Briefs November/December 2002 A research-based newsletter prepared by the University of California for professionals interested in maternal and infant nutrition Recent Trends
More informationAMERICAN ACADEMY OF PEDIATRICS. Health Supervision for Children With Sickle Cell Disease
AMERICAN ACADEMY OF PEDIATRICS Section on Hematology/Oncology Committee on Genetics Health Supervision for Children With Sickle Cell Disease ABSTRACT. Sickle cell disease (SCD) is a group of complex genetic
More informationPneumococcal 13-valent Conjugate Vaccine Biological Page
Pneumococcal 13-valent Conjugate Vaccine Biological Page Section 7: Biological Product Information Standard #: 07.291 Created by: Province-wide Immunization Program Standards and Quality Approved by: Province-wide
More informationPEDIATRIC PREVENTIVE HEALTH GUIDELINES
PEDIATRIC PREVENTIVE HEALTH GUIDELINES Each child and family is unique; therefore, these Guidelines for Preventive Pediatric Health Care are designed for the care of children who are receiving competent
More information